“We’ve seen massive, massive price increases, and shame has not trumped profit. After a while, people get numb to it,” said Adams Dudley, a pulmonologist and director of the University of California, San Francisco’s Center for Healthcare Value. Indeed, both Valeant and Teva have weathered these controversies before — just not in advance of an actual price hike.”

Victoria Colliver, March 23, 2018

“But the pharmaceutical industry hasn’t changed its ways since Trump took office: 20 drugs have seen price hikes of 200% or more since January 2017 …These increases, which can be found in an analysis by Pharmacy Benefits Consultants, are in the drugs’ list prices, before rebates and discounts are applied. People with insurance don’t pay these full amounts, but price hikes still affect everyone.”

Sam Baker, March 21, 2018

“But several experts and advocacy groups say policies in the administration’s latest budget proposal don’t tackle the biggest driver of high prices: Nothing prevents a drugmaker from setting a price at whatever level it wants.”

Robert King, March 13, 2018

“And price hikes continue for already expensive newer drugs …Drugmakers like to say prices keep rising because pharmacy benefit managers demand ever-bigger discounts for their clients, forcing drugmakers to raise list prices to keep up. But…drug companies do plenty of price-hiking for drugs such as Revlimid that aren’t really discounted.”

Max Nisen, March 9, 2018

“But large increases still happen. Last month alone, Wells Fargo analyst David Maris tracked the 50 biggest price increases on medicines, the largest of which was a 948.4 percent increase on a drug from Torrent Pharmaceuticals. And data from Rx Savings Solutions show price increases of less than 10 percent on expensive medicines can result in adding thousands of dollars to their cost.”

Meg Tirrell, March 9, 2018

“A more typical play for drug companies — the Humira play — is to start at a high price and keep raising it ever higher, but incrementally …AbbVie joined a few of its rivals in saying it would limit price increases to single digits this year, and so only raised Humira by another 9.7 percent this month, roughly four and a half times the inflation rate. For the drug industry, that counts as generosity.”

Danny Hakim, January 6, 2018